Instrument Inactif

Communiqués Onconova Therapeutics Inc Nasdaq

Actions

US68232V1089

Recherche biotechnologique et médicale

Communiqués

22/06	Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program	AQ
12/06	Traws Pharma Provides Regulatory Update on Influenza Program	AQ
27/05	Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks	AQ
15/05	Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results	AQ
11/05	Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections	AQ
08/05	Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections	AQ
15/04	Traws Pharma : Annual Report for Fiscal Year Ending 12-31, 2024 (Form 10-K)	PU
15/04	Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights	AQ
15/04	Traws Pharma Announces Up to $60 Million Private Placement Financing	AQ
20/02	Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil	AQ
19/02	Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza	AQ
26/01	Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza	AQ
14/01	Traws Pharma Files Tivoxavir Marboxil Investigational New Drug Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir	AQ
13/01	Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients	AQ
17/12	Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients	AQ
13/11	Traws Pharma : Corporate Deck, November 2025	PU
13/11	Traws Pharma Reports Third Quarter 2025 Results and Business Highlights	AQ
30/10/25	ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials	PR
23/10/25	Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.	PR
14/10/25	Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025	AQ
06/10/25	Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives	AQ
18/08/25	Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025	AQ
15/08/25	Traws Pharma Reports Second Quarter 2025 Results and Business Highlights	AQ
14/08/25	Traws Pharma Reports Second Quarter 2025 Results and Business Highlights	AQ
08/08/25	Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025	AQ